BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37099047)

  • 1. Detecting localised prostate cancer using radiomic features in PSMA PET and multiparametric MRI for biologically targeted radiation therapy.
    Chan TH; Haworth A; Wang A; Osanlouy M; Williams S; Mitchell C; Hofman MS; Hicks RJ; Murphy DG; Reynolds HM
    EJNMMI Res; 2023 Apr; 13(1):34. PubMed ID: 37099047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Voxel-wise correlation of positron emission tomography/computed tomography with multiparametric magnetic resonance imaging and histology of the prostate using a sophisticated registration framework.
    Reynolds HM; Williams S; Jackson P; Mitchell C; Hofman MS; Hicks RJ; Murphy DG; Haworth A
    BJU Int; 2019 Jun; 123(6):1020-1030. PubMed ID: 30536698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Semi-quantitative and quantitative dynamic contrast-enhanced (DCE) MRI parameters as prostate cancer imaging biomarkers for biologically targeted radiation therapy.
    Reynolds HM; Tadimalla S; Wang YF; Montazerolghaem M; Sun Y; Williams S; Mitchell C; Finnegan ME; Murphy DG; Haworth A
    Cancer Imaging; 2022 Dec; 22(1):71. PubMed ID: 36536464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic accuracy of
    Scheltema MJ; Chang JI; Stricker PD; van Leeuwen PJ; Nguyen QA; Ho B; Delprado W; Lee J; Thompson JE; Cusick T; Spriensma AS; Siriwardana AR; Yuen C; Kooner R; Hruby G; O'Neill G; Emmett L
    BJU Int; 2019 Nov; 124 Suppl 1():42-49. PubMed ID: 31287613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The added value of PSMA PET/MR radiomics for prostate cancer staging.
    Solari EL; Gafita A; Schachoff S; Bogdanović B; Villagrán Asiares A; Amiel T; Hui W; Rauscher I; Visvikis D; Maurer T; Schwamborn K; Mustafa M; Weber W; Navab N; Eiber M; Hatt M; Nekolla SG
    Eur J Nucl Med Mol Imaging; 2022 Jan; 49(2):527-538. PubMed ID: 34255130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective Evaluation of
    Gaur S; Mena E; Harmon SA; Lindenberg ML; Adler S; Ton AT; Shih JH; Mehralivand S; Merino MJ; Wood BJ; Pinto PA; Mease RC; Pomper MG; Choyke PL; Turkbey B
    AJR Am J Roentgenol; 2020 Sep; 215(3):652-659. PubMed ID: 32755168
    [No Abstract]   [Full Text] [Related]  

  • 7. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and
    Franklin A; Yaxley WJ; Raveenthiran S; Coughlin G; Gianduzzo T; Kua B; McEwan L; Wong D; Delahunt B; Egevad L; Samaratunga H; Brown N; Parkinson R; Roberts MJ; Yaxley JW
    BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using multiparametric Magnetic Resonance Imaging and Prostate Specific Membrane Antigen Positron Emission Tomography to detect and delineate the gross tumour volume of intraprostatic lesions - A systematic review and meta-analysis.
    Dhar A; Cendejas-Gomez JJ; Castro Mendez L; Boldt G; McArthur E; Zamboglou C; Bauman G
    Radiother Oncol; 2024 Mar; 192():110070. PubMed ID: 38262815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of
    Zamboglou C; Drendel V; Jilg CA; Rischke HC; Beck TI; Schultze-Seemann W; Krauss T; Mix M; Schiller F; Wetterauer U; Werner M; Langer M; Bock M; Meyer PT; Grosu AL
    Theranostics; 2017; 7(1):228-237. PubMed ID: 28042330
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Ferraro DA; Hötker AM; Becker AS; Mebert I; Laudicella R; Baltensperger A; Rupp NJ; Rueschoff JH; Müller J; Mortezavi A; Sapienza MT; Eberli D; Donati OF; Burger IA
    Eur J Hybrid Imaging; 2022 Jul; 6(1):14. PubMed ID: 35843966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic value of integrated
    Zeng Y; Leng X; Liao H; Jiang G; Chen P
    Prostate Int; 2022 Jun; 10(2):108-116. PubMed ID: 35510079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection and localisation of primary prostate cancer using
    Kalapara AA; Nzenza T; Pan HYC; Ballok Z; Ramdave S; O'Sullivan R; Ryan A; Cherk M; Hofman MS; Konety BR; Lawrentschuk N; Bolton D; Murphy DG; Grummet JP; Frydenberg M
    BJU Int; 2020 Jul; 126(1):83-90. PubMed ID: 31260602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer.
    Amin A; Blazevski A; Thompson J; Scheltema MJ; Hofman MS; Murphy D; Lawrentschuk N; Sathianathen N; Kapoor J; Woo HH; Chalasani V; Rasiah K; van Leeuwen PJ; Tang R; Cusick T; Stricker P; Emmett L
    BJU Int; 2020 Apr; 125(4):515-524. PubMed ID: 31957122
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Donato P; Morton A; Yaxley J; Ranasinghe S; Teloken PE; Kyle S; Coughlin G; Esler R; Dunglison N; Gardiner RA; Roberts MJ
    Eur J Nucl Med Mol Imaging; 2020 Jul; 47(8):1843-1851. PubMed ID: 31912257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of machine learning algorithms to predict clinically significant prostate cancer of the peripheral zone with multiparametric MRI using clinical assessment categories and radiomic features.
    Bernatz S; Ackermann J; Mandel P; Kaltenbach B; Zhdanovich Y; Harter PN; Döring C; Hammerstingl R; Bodelle B; Smith K; Bucher A; Albrecht M; Rosbach N; Basten L; Yel I; Wenzel M; Bankov K; Koch I; Chun FK; Köllermann J; Wild PJ; Vogl TJ
    Eur Radiol; 2020 Dec; 30(12):6757-6769. PubMed ID: 32676784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous
    Eiber M; Weirich G; Holzapfel K; Souvatzoglou M; Haller B; Rauscher I; Beer AJ; Wester HJ; Gschwend J; Schwaiger M; Maurer T
    Eur Urol; 2016 Nov; 70(5):829-836. PubMed ID: 26795686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synchronous vs independent reading of prostate-specific membrane antigen positron emission tomography (PSMA-PET) and magnetic resonance imaging (MRI) to improve diagnosis of prostate cancer.
    Doan P; Counter W; Papa N; Sheehan-Dare G; Ho B; Lee J; Liu V; Thompson JE; Agrawal S; Roberts MJ; Buteau J; Hofman MS; Moon D; Lawrentschuk N; Murphy D; Stricker PD; Emmett L
    BJU Int; 2023 May; 131(5):588-595. PubMed ID: 36371669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PEDAL protocol: a prospective single-arm paired comparison of multiparametric MRI and 18F-DCPFyl PSMA PET/CT to diagnose prostate cancer.
    Tran V; Hong A; Sutherland T; Taubman K; Lee SF; Lenaghan D; Sethi K; Corcoran NM; Lawrentschuk N; Woo H; Tarlinton L; Bolton D; Spelman T; Thomas L; Booth R; Hegarty J; Perry E; Wong LM
    BMJ Open; 2022 Sep; 12(9):e061815. PubMed ID: 36123093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [
    Bettermann AS; Zamboglou C; Kiefer S; Jilg CA; Spohn S; Kranz-Rudolph J; Fassbender TF; Bronsert P; Nicolay NH; Gratzke C; Bock M; Ruf J; Benndorf M; Grosu AL
    Radiother Oncol; 2019 Dec; 141():214-219. PubMed ID: 31431366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual time point imaging of staging PSMA PET/CT quantification; spread and radiomic analyses.
    Aksu A; Vural Topuz Ö; Yılmaz G; Çapa Kaya G; Yılmaz B
    Ann Nucl Med; 2022 Mar; 36(3):310-318. PubMed ID: 34988888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.